Endostar, an Antiangiogenesis Inhibitor, Combined With Chemoradiotherapy for Locally Advanced Cervical Cancer

This phase II randomized clinical trial aimed to assess the efficacy and toxicity of Endostar, an antiangiogenesis inhibitor, combined with concurrent chemoradiotherapy (CCRT) for locally advanced cervical cancer (LACC). Patients with LACC were randomly assigned to either CCRT plus Endostar (CCRT+E...

Descripción completa

Detalles Bibliográficos
Autores principales: Lu, Heming, Wu, Yuying, Liu, Xu, Huang, Huixian, Jiang, Hailan, Zhu, Chaohua, Man, Yuping, Chen, Zhaohong, Long, Xianfeng, Pang, Qiang, Peng, Luxing, Li, Xianglong, Gu, Junzhao, Deng, Shan, Xing, Ligang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Cognizant Communication Corporation 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8790112/
https://www.ncbi.nlm.nih.gov/pubmed/34544526
http://dx.doi.org/10.3727/096504021X16318716607908

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8790112/
https://www.ncbi.nlm.nih.gov/pubmed/34544526
http://dx.doi.org/10.3727/096504021X16318716607908

Ejemplares similares